Abstract: Chronic graft-versus-host disease (cGVHD) is a severe, life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT), characterized by systemic inflammation and irreversible tissue fibrosis. While systemic corticosteroids remain the standard first-line therapy, a significant proportion of patients develop steroid-refractory or steroid-dependent disease, necessitating alternative treatments. KD025, known generically as belumosudil, has emerged as a breakthrough targeted therapy for cGVHD. As a selective oral inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), belumosudil possesses a unique dual mechanism of action that simultaneously restores immune homeostasis and directly inhibits profibrotic pathways. Clinical trials, notably the ROCKstar study, have demonstrated its robust efficacy across multiple organ systems and a favorable safety profile, leading to its regulatory approval. This comprehensive literature review synthesizes current knowledge on belumosudil, detailing its pharmacological activity, molecular mechanisms, structure-activity relationship, current clinical limitations, and future therapeutic perspectives in the management of cGVHD.
1. Introduction
Chronic graft-versus-host disease (cGVHD) occurs in 30% to 70% of patients who undergo allogeneic hematopoietic stem cell transplantation (HSCT) and is a leading cause of non-relapse morbidity and mortality [1][4]. The pathogenesis of cGVHD is multiphasic, beginning with acute inflammation and tissue injury, progressing to immune dysregulation involving alloreactive T- and B-cells, and ultimately culminating in aberrant tissue repair and irreversible fibrosis [2][4]. This fibrotic phase can affect multiple organs, including the skin, eyes, mouth, gastrointestinal tract, liver, and lungs, severely impairing patients' quality of life [2][7].
Systemic corticosteroids, often combined with calcineurin inhibitors, are the standard first-line treatment for cGVHD. However, up to 70% of patients experience suboptimal disease control and become steroid-dependent or steroid-refractory, requiring second-line therapies [2]. Historically, treatment options for steroid-refractory cGVHD were limited and associated with significant immunosuppressive toxicities. The therapeutic landscape has recently shifted toward targeted agents, including ruxolitinib, ibrutinib, and belumosudil [4][8]. Belumosudil (KD025) was approved by the US Food and Drug Administration (FDA) in July 2021 for the treatment of adult and pediatric patients aged 12 years and older with cGVHD after the failure of at least two prior lines of systemic therapy [3][4]. Its approval marks a significant milestone due to its novel mechanism targeting both the inflammatory and fibrotic hallmarks of the disease.
2. Pharmacological Activity
The clinical efficacy of belumosudil was primarily established in the pivotal phase II, randomized, multicenter ROCKstar trial (NCT03640481). In this study, heavily pretreated patients with persistent cGVHD (median of three prior lines of systemic therapy) received belumosudil at either 200 mg once daily or 200 mg twice daily [2][3]. The overall response rate (ORR) was highly promising, reaching 74% in the once-daily cohort and 77% in the twice-daily cohort [3][8]. Responses were durable, with a median duration of response of 54 weeks, and a 12-month failure-free survival (FFS) rate of 56% [2][3].
Belumosudil demonstrates broad organ-specific activity. High response rates were observed in fibrotic and sclerotic manifestations, which are traditionally difficult to treat. Specifically, the ROCKstar trial reported ORRs of 71% to 75% in joints and fascia, 69% in the lower gastrointestinal tract, and 55% to 66% in the mouth [1][2][8]. While response rates in the lungs (e.g., bronchiolitis obliterans syndrome, BOS) were comparatively lower (17% to 26%), early intervention in patients with less advanced lung involvement showed more favorable outcomes [1][2]. Furthermore, belumosudil treatment led to clinically meaningful improvements in patient-reported outcomes, with approximately 60% of patients experiencing a significant reduction in the Lee Symptom Scale (LSS) score, and 65% successfully reducing their corticosteroid doses [3][4].
Real-world data corroborate these clinical trial findings, showing that belumosudil is effective even in patients who have previously failed other targeted therapies like ruxolitinib or ibrutinib [2]. From a safety perspective, belumosudil is well-tolerated. Because it acts as an immunomodulator rather than a broad immunosuppressant, it carries a lower risk of severe infections (such as cytomegalovirus reactivation) and hematologic toxicities (like severe cytopenias) compared to other agents like ruxolitinib and ibrutinib [2][5]. Common adverse events include fatigue, diarrhea, nausea, and mild liver enzyme elevations [4].
3. Molecular Mechanism of Action
The pathogenesis of cGVHD is heavily driven by the dysregulation of the Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) signaling pathway [2]. Belumosudil exerts its therapeutic effects through a unique dual mechanism of action: it simultaneously corrects immune dysregulation and directly inhibits aberrant tissue fibrosis [2][6].
Immunologically, ROCK2 regulates the balance between pro-inflammatory T helper 17 (Th17) cells and immunosuppressive regulatory T (Treg) cells. Belumosudil inhibits ROCK2, which subsequently downregulates the phosphorylation of signal transducer and activator of transcription 3 (STAT3). This downregulation prevents the formation of the JAK2/STAT3 complex, reducing the expression of transcription factors like RORγt and Bcl6, thereby suppressing the differentiation and activity of Th17 and T follicular helper (Tfh) cells [2][4]. Concurrently, ROCK2 inhibition upregulates the phosphorylation of STAT5, which enhances the proliferation and function of Treg cells. This shift in the Th17/Treg balance restores immune homeostasis and reduces the secretion of pro-inflammatory cytokines such as IL-17 and IL-21 [2][3][6].
Fibrotically, ROCK2 signaling is a critical driver of myofibroblast activation and collagen deposition. Activated ROCK2 facilitates the expression of profibrotic genes, including connective tissue growth factor (CTGF), fibronectin 1, and collagen types I and IV [2]. By inhibiting ROCK2, belumosudil blocks these profibrotic mediators, preventing the differentiation of fibroblasts into myofibroblasts and halting the progression of nonreversible fibrosis in target organs [2][4]. Preclinical models have demonstrated that belumosudil can significantly reduce and even reverse fibrosis in the lungs, skin, and liver [2][6].
4. Structure-Activity Relationship (SAR)
The therapeutic index and safety profile of belumosudil are deeply tied to its kinase selectivity. Belumosudil is a highly selective inhibitor of the ROCK2 isoform. Pharmacodynamic profiling reveals that belumosudil inhibits ROCK2 with a half-maximal inhibitory concentration (IC50) of approximately 100 nM, whereas its IC50 for the closely related ROCK1 isoform is approximately 3 µM [3]. This represents a roughly 30-fold selectivity for ROCK2 over ROCK1. This isoform-specific targeting is crucial; while ROCK2 is predominantly involved in immune modulation and fibrotic processes, broad inhibition of both ROCK1 and ROCK2 could lead to unwanted off-target systemic toxicities, such as severe hypotension. The selective structural binding of belumosudil allows for the targeted suppression of pathogenic Th17 cells and fibrotic pathways while maintaining a favorable safety and tolerability profile [2][3].
5. Current Limitations
Despite its significant efficacy, the clinical use of belumosudil is accompanied by several limitations. First, while it shows excellent response rates in joints, fascia, and the gastrointestinal tract, its efficacy in treating severe pulmonary cGVHD, such as advanced bronchiolitis obliterans syndrome (BOS), is limited. Response rates in the lungs are notably lower (0% to 26%), indicating that once extensive pulmonary fibrosis is established, it may be irreversible even with ROCK2 inhibition [1][2].
Second, there are important pharmacokinetic interactions to consider. Belumosudil requires dose modifications (increased to 200 mg twice daily) when co-administered with strong CYP3A4 inducers or proton pump inhibitors [2][3]. Additionally, belumosudil can impact the pharmacokinetics of concurrent immunosuppressants; it has been shown to increase the concentration-dose ratio of calcineurin inhibitors (like tacrolimus) and mTOR inhibitors (like sirolimus), necessitating careful therapeutic drug monitoring and potential dose reductions to prevent over-immunosuppression [2].
Finally, as a relatively new agent, the long-term safety of prolonged ROCK2 inhibition in immunocompromised HSCT recipients remains to be fully elucidated. Furthermore, while clinical resistance to belumosudil has not yet been widely reported, the potential for acquired drug resistance with long-term use—as seen with other kinase inhibitors like ruxolitinib—remains a theoretical concern that requires ongoing surveillance [2].
6. Future Perspectives
The future clinical development of belumosudil is focused on expanding its utility earlier in the disease course and in novel combinations. Several phase II and III trials are currently investigating belumosudil as a first-line or pre-emptive therapy for newly diagnosed cGVHD (e.g., the ROCKnrol-1 trial combining it with corticosteroids) and for early-stage BOS (the BEBOP trial) [2]. Moving the drug to earlier lines of therapy may prevent the onset of irreversible fibrosis and reduce the overall cumulative exposure to toxic corticosteroids.
Combination strategies are also a major area of interest. Real-world data and preliminary studies suggest that combining belumosudil with ruxolitinib or B-cell targeted therapies (like rituximab) is well-tolerated and may yield synergistic efficacy, particularly in patients with severe, multiorgan, refractory disease [2]. Additionally, the development of advanced drug delivery systems and novel formulations, such as a recently tested oral suspension of belumosudil, will greatly benefit pediatric patients and adults with oral cGVHD or dysphagia who struggle to swallow tablets [2].
Finally, the identification and validation of predictive biomarkers—such as ST2, soluble B-cell activating factor (BAFF), CXCL9, and CXCL10—will be critical for patient stratification. Integrating these biomarkers into clinical practice could help clinicians identify which patients are most likely to respond to ROCK2 inhibition, paving the way for truly personalized management of cGVHD [2].
